Stocks and Investing Stocks and Investing
Fri, September 29, 2023
Thu, September 28, 2023
Wed, September 27, 2023
Tue, September 26, 2023

Uy Ear Reiterated (SRPT) at Strong Buy and Held Target at $160 on, Sep 26th, 2023


Published on 2024-10-28 06:34:27 - WOPRAI, Uy Ear
  Print publication without navigation


Uy Ear of Mizuho, Reiterated "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy and Held Target at $160 on, Sep 26th, 2023.

Uy has made no other calls on SRPT in the last 4 months.



There are 10 other peers that have a rating on SRPT. Out of the 10 peers that are also analyzing SRPT, 2 agree with Uy's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Judah Frommer of "Credit Suisse" Reiterated at Hold and Held Target at $141 on, Friday, June 23rd, 2023
  • Gavin Clark-Gartner of "Evercore ISI Group" Downgraded from Buy to Hold and Held Target at $139 on, Friday, June 23rd, 2023


These are the ratings of the 8 analyists that currently disagree with Uy


  • Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $223 on, Thursday, August 3rd, 2023
  • Gil Blum of "Needham" Reiterated at Strong Buy and Held Target at $185 on, Thursday, August 3rd, 2023
  • Matthew Harrison of "Morgan Stanley" Reiterated at Buy and Held Target at $183 on, Thursday, August 3rd, 2023
  • Neena Bitritto-Garg of "Citigroup" Maintained at Strong Buy with Increased Target to $204 on, Friday, June 23rd, 2023
  • Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $215 on, Friday, June 23rd, 2023
  • Kristen Kluska of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $166 on, Friday, June 23rd, 2023
  • Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $213 on, Friday, June 23rd, 2023
  • Hartaj Singh of "Oppenheimer" Reiterated at Buy and Held Target at $180 on, Friday, May 26th, 2023